# [302] PLACING THE SURGEON IN THE CENTER - A NOVEL 3D VISUALIZATION PLATFORM FOR EYE SURGERY PROVIDING TRANSPARENT DISPLAY, DATA OVERLAY AND GUIDANCE

<u>ron schneider</u><sup>1</sup>, Anat Loewenstein<sup>2</sup>, Adiel Barak<sup>3</sup>, Avi Zeitouny<sup>4</sup>, <sup>1</sup> Elbit Systems; Beyeonics Surgical, <sup>2</sup> Sackler Faculty of Medicine; Tel Aviv University, <sup>3</sup> Tel Aviv Medical Center; Department Ophthalmology, <sup>4</sup> Elbit Systems

#### **Investment Rational**

BeyeOnics develops a fully integrated surgeon-centered visualization augmented reality video microscope for use in ophthalmic surgery (mainly cataract and vitreoretinal). The system provides a constant stream of information to the surgeon to create the perfect intra-operative decision making environment. BeyeOnics management is based on leading experts from the technology and business in aviation together with world leading surgeons.

## **Business Strategy**

BeyeOnics offers to the costumers Comprehensive OR visualization system providing full needs solutions with surgical software applications growth capabilities. The system competes directly with surgical microscope companies with roughly the same pricing and increased capabilities. Near term revenues - the company will sale systems to key facilities. Long term revenues - unique guidance disposables and surgical software applications.

## **Core Technology**

The technology leverages knowhow from state-of-the-art fighter pilot head mounted displays, ultra-resolution imaging and zero latency embedded computer vision. Combined, the technology offers unparalleled performance to surgeons. With surgical application and data availability the system potentially allows for a more accurate surgery and increased safety. In addition, the system eliminates surgeon discomfort associated with microscope use in the operating room.

#### **Product Profile/Pipeline**

The company will launch soon its first product – the augmented reality video microscope. Right after the company will offer surgical applications to the costumers. The system was successful in early clinical trials and the product is expected to receive 510k very soon. The market potential is >1B\$ for the capital equipment alone and exceeds a lot 1B\$ combined with disposables and sw.